Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Boston Scientific
Hauser calls out the FDA, Guidant on recalled devices | MassDevice.com On Call
MASSDEVICE ON CALL — It was the death of a 21-year-old patient whose implanted cardiac defibrillator failed to shock his heart back to normal rhythm that started Dr. Robert Hauser on the path to becoming a vocal advocate for change at the FDA.
Joshua Oukrop, just a teenager when he received a Guidant ICD for a congenital heart condition, died when the implant shorted out instead of providing the necessary shock to his heart.
Boston Scientific’s Alair asthma treatment gets a thumbs-up | Regulatory Roundup
Incoming BSX CEO Mahoney’s 2011 total tops $11.5M | Personnel Moves
ACC 2012: Stent news from Medtronic, Boston Scientific, OrbusNeich
ACC 2012: Boston Scientific swats stent deformation concerns
Boston Scientific (NYSE:BSX) sought to dispel concerns that its thinner next-generation stents may be more prone to crumpling than some other models with the release of results from 2 randomized clinical trials which found no instances of deformation with the med-tech titan’s newest stents.
Stent Wars: DES best bare metal stents
Updated March 26, 2012 at 9:23 a.m. with new details on Promus/Xience private label deal and March 23, 2012 at 1:15 p.m. with comments from Medtronic.
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
Johnson & Johnson sold vaginal mesh product for 3 years without FDA clearance, report says
Health care giant Johnson & Johnson (NYSE:JNJ) found itself again in the hot seat as new reports claim the company sold a transvaginal mesh product in the U.S. for 3 years before obtaining appropriate FDA clearance.
MassDevice.com +3 | The top 3 med-tech stories for March 19, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.